Literature DB >> 11154251

The discount rate in the economic evaluation of prevention: a thought experiment.

L Bonneux1, E Birnie.   

Abstract

OBJECTIVES: In the standard economic model of evaluation, constant discount rates devalue the long term health benefits of prevention strongly. This study shows that it is unlikely that this reflects societal preference.
DESIGN: A thought experiment in a cause elimination life table calculates savings of eliminating cardiovascular disease from the Dutch population. A cost effectiveness analysis calculates the acceptable costs of such an intervention at a threshold of 18 000 Euro per saved life year.
METHODS: Cause specific mortality (all cardiovascular causes of death and all other causes) and health care costs (all costs of cardiovascular disease and all other causes of costs) by age and male sex of 1994.
RESULTS: At a 0% discount rate, an intervention eliminating cardiovascular disease may cost 71 100 Euro. At the same threshold but at discount rates of 3% or 6%, the same intervention may cost 8100 Euro (8.8 times less) or 1100 Euro (65 times less).
CONCLUSIONS: The standard economic model needs more realistic duration dependent models of time preference, which reflect societal preference.

Entities:  

Mesh:

Year:  2001        PMID: 11154251      PMCID: PMC1731836          DOI: 10.1136/jech.55.2.123

Source DB:  PubMed          Journal:  J Epidemiol Community Health        ISSN: 0143-005X            Impact factor:   3.710


  9 in total

Review 1.  Discounting the future: influence of the economic model.

Authors:  R R West
Journal:  J Epidemiol Community Health       Date:  1996-06       Impact factor: 3.710

2.  Discounting costs and effects: a reconsideration.

Authors:  B A van Hout
Journal:  Health Econ       Date:  1998-11       Impact factor: 3.046

3.  [Economic evaluation of cardiology; background and application].

Authors:  B A van Hout; E S Goes; E W Grijseels; M A Quarles van Ufford
Journal:  Ned Tijdschr Geneeskd       Date:  1998-09-19

4.  Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party.

Authors:  M F Drummond; T O Jefferson
Journal:  BMJ       Date:  1996-08-03

Review 5.  Saving future lives. A comparison of three discounting models.

Authors:  J A Cairns; M M van der Pol
Journal:  Health Econ       Date:  1997 Jul-Aug       Impact factor: 3.046

6.  Time preferences for health gains: an empirical investigation.

Authors:  J A Olsen
Journal:  Health Econ       Date:  1993-10       Impact factor: 3.046

7.  Foundations of cost-effectiveness analysis for health and medical practices.

Authors:  M C Weinstein; W B Stason
Journal:  N Engl J Med       Date:  1977-03-31       Impact factor: 91.245

8.  Preventing fatal diseases increases healthcare costs: cause elimination life table approach.

Authors:  L Bonneux; J J Barendregt; W J Nusselder; P J der Maas
Journal:  BMJ       Date:  1998-01-03

9.  Demographic and epidemiological determinants of healthcare costs in Netherlands: cost of illness study.

Authors:  W J Meerding; L Bonneux; J J Polder; M A Koopmanschap; P J van der Maas
Journal:  BMJ       Date:  1998-07-11
  9 in total
  17 in total

1.  Economic evaluation of a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in older adults in Switzerland.

Authors:  Thomas D Szucs; Reto W Kressig; Manto Papageorgiou; Werner Kempf; Jean-Pierre Michel; Anton Fendl; Xavier Bresse
Journal:  Hum Vaccin       Date:  2011-07-01

2.  Costs to implement an effective transition-to-parenthood program for couples: analysis of the Family Foundations program.

Authors:  Damon E Jones; Mark E Feinberg; Michelle L Hostetler
Journal:  Eval Program Plann       Date:  2014-02-11

3.  How to measure the burden of mortality?

Authors:  L Bonneux
Journal:  J Epidemiol Community Health       Date:  2002-02       Impact factor: 3.710

4.  A health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UK.

Authors:  Lee Moore; Vanessa Remy; Monique Martin; Maud Beillat; Alistair McGuire
Journal:  Cost Eff Resour Alloc       Date:  2010-04-30

5.  The Economic Value of Vaccination: Why Prevention is Wealth.

Authors: 
Journal:  J Mark Access Health Policy       Date:  2015-08-12

6.  Cost-effectiveness of different human papillomavirus vaccines in Singapore.

Authors:  Vernon J Lee; Sun Kuie Tay; Yee Leong Teoh; Mei Yin Tok
Journal:  BMC Public Health       Date:  2011-03-31       Impact factor: 3.295

7.  Integration of a smoking cessation program in the treatment protocol for patients with head and neck and lung cancer.

Authors:  J C de Bruin-Visser; A H Ackerstaff; H Rehorst; V P Retèl; F J M Hilgers
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-06-23       Impact factor: 2.503

8.  Future costs in cost-effectiveness analysis: an empirical assessment.

Authors:  Marie Kruse; Jan Sørensen; Dorte Gyrd-Hansen
Journal:  Eur J Health Econ       Date:  2010-09-28

9.  The impact of infection on population health: results of the Ontario burden of infectious diseases study.

Authors:  Jeffrey C Kwong; Sujitha Ratnasingham; Michael A Campitelli; Nick Daneman; Shelley L Deeks; Douglas G Manuel; Vanessa G Allen; Ahmed M Bayoumi; Aamir Fazil; David N Fisman; Andrea S Gershon; Effie Gournis; E Jenny Heathcote; Frances B Jamieson; Prabhat Jha; Kamran M Khan; Shannon E Majowicz; Tony Mazzulli; Allison J McGeer; Matthew P Muller; Abhishek Raut; Elizabeth Rea; Robert S Remis; Rita Shahin; Alissa J Wright; Brandon Zagorski; Natasha S Crowcroft
Journal:  PLoS One       Date:  2012-09-04       Impact factor: 3.240

10.  The economics of primary prevention of cardiovascular disease - a systematic review of economic evaluations.

Authors:  David Lb Schwappach; Till A Boluarte; Marc Suhrcke
Journal:  Cost Eff Resour Alloc       Date:  2007-05-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.